Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE:DRREDDY) (NYSE:RDY) reported on Friday the availability of Abiraterone Acetate Tablets USP in the US market in 250 mg tablets in bottle count sizes of 120.
The company added that Abiraterone Acetate Tablets USP, 250 mg is the therapeutic equivalent generic version of Zytiga (abiraterone acetate), which has been approved by the US Food and Drug Administration (USFDA).
For the most recent 12 months ending in March 2020, Zytiga brand and generic market had US sales of about USD454m MAT, according to IQVIA Health.
Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer, added the company.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream